Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A June 25 rating update from Leerink pushed up its price target for Eli Lilly and Company, according to a market wrap published by Yahoo Finance on June 27. The note underscores how analysts are positioning around the company’s growth outlook as investors continue to weigh new demand and competitive risk.
THE APEX TIMES
THE APEX TIMES
Eli Lilly’s stock rose sharply in the afternoon session after a European Medicines Agency panel endorsed the company’s Jaypirca in a cancer-related decision, underscoring how quickly drug-regulatory momentum can move sentiment in biotech and big pharma.
THE APEX TIMES
Eli Lilly, AbbVie and Johnson & Johnson rose again as investors kept rewarding the large U.S. drugmakers, according to a market report published Tuesday.
THE APEX TIMES
Blair Jackson, set to take over at Alkermes, said the next 12 months could be a defining stretch as the company positions itself for the race to develop and commercialize orexin treatments for sleep disorders.
THE APEX TIMES
A Pennsylvania speech that included references to Eli Lilly and Nokia underscored how public remarks about individual companies can feed into trading attention, even as questions persist about how related party stock transactions are handled while a president is in office.
THE APEX TIMES
Lilly’s stock rose sharply after the EU’s medicines committee recommended using Jaypirca (pirtobrutinib) in a broader adult population, a step that could expand the drug’s addressable market in Europe.
THE APEX TIMES
A new collaboration links Charles River Laboratories’ standardized nonclinical testing services with Eli Lilly’s Lilly TuneLab, a platform aimed at helping developers evaluate candidate medicines created with AI and machine learning.
THE APEX TIMES
A favorable opinion from the EMA’s CHMP puts Lilly’s Jaypirca one step closer to potential approval in the European Union for adults with chronic lymphocytic leukemia, covering all lines of therapy.
THE APEX TIMES
A new round of funding will support the biotech’s next clinical steps after it reported early Phase I results, positioning the company to push its lead therapy further for two difficult-to-treat conditions.
